Mitochondrial Dysfunction

R&D

Partner Content

Uncover mitochondrial pathogenic mechanisms to show clinical efficacy for regulatory success

Events

Partner Content

Therapies for mitochondrial dysfunction

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.